MEIP - MEI Pharma Inc Stock Price, Fair Value and News

3.15USD+0.22 (+7.51%)Market Closed

Market Summary

USD3.15+0.22

Market Closed

7.51%

MEIP Stock Price

View Fullscreen

MEIP RSI Chart

MEIP Valuation

Market Cap

21.0M

Price/Earnings (Trailing)

0.8

Price/Sales (Trailing)

0.31

Price/Free Cashflow

-0.48

MEIP Price/Sales (Trailing)

MEIP Profitability

Return on Equity

51.26%

Return on Assets

36.7%

Free Cashflow Yield

-208.58%

MEIP Fundamentals

MEIP Revenue

Revenue (TTM)

66.8M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

MEIP Earnings

Earnings (TTM)

26.2M

Earnings Growth (Yr)

40.88%

Earnings Growth (Qtr)

17.5%

Breaking Down MEIP Revenue

Last 7 days

4.3%

Last 30 days

-4.8%

Last 90 days

-28.2%

Trailing 12 Months

-57.9%

How does MEIP drawdown profile look like?

MEIP Financial Health

Current Ratio

6.17

MEIP Investor Care

Diluted EPS (TTM)

3.92

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	66.8M	0	0	0
2023	58.8M	48.8M	105.4M	72.6M
2022	36.7M	40.7M	41.7M	62.6M
2021	52.8M	34.8M	35.9M	35.2M
2020	4.5M	28.9M	34.4M	46.0M
2019	4.3M	4.9M	5.6M	4.5M
2018	7.0M	1.6M	1.8M	3.5M
2017	18.6M	23.2M	17.8M	12.4M
2016	118.0K	4.7M	9.4M	14.0M
2015	71.0K	78.0K	93.0K	109.0K
2014	79.0K	81.0K	75.0K	60.0K
2013	22.0K	37.0K	52.0K	75.0K
2012	61.8K	39.0K	39.0K	39.0K
2011	0	130.0K	107.3K	84.5K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of MEI Pharma Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 20, 2023	funicular funds, lp	acquired	844,200	7.00	120,600	-
Oct 20, 2023	anson funds management lp	acquired	1,253,000	7.00	179,000	-
Oct 11, 2023	funicular funds, lp	acquired	210,000	7.00	30,000	-
Oct 11, 2023	anson funds management lp	acquired	350,000	7.00	50,000	-
Sep 22, 2023	funicular funds, lp	bought	219,554	6.8525	32,040	-
Sep 22, 2023	anson funds management lp	bought	329,331	6.8525	48,060	-
Sep 21, 2023	funicular funds, lp	bought	144,740	6.4616	22,400	-
Sep 21, 2023	anson funds management lp	bought	217,110	6.4616	33,600	-
Sep 20, 2023	funicular funds, lp	bought	480,744	6.0093	80,000	-
Sep 20, 2023	anson funds management lp	bought	721,116	6.0093	120,000	-

Which funds bought or sold MEIP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-32,078	71,284	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	-10,562	23,472	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-0.62	-1,179	2,568	-%
May 15, 2024	Cable Car Capital LLC	unchanged	-	-1,100,590	2,445,760	3.38%
May 15, 2024	Tower Research Capital LLC (TRC)	added	45.52	27.00	7,724	-%
May 15, 2024	TANG CAPITAL MANAGEMENT LLC	sold off	-100	-1,891,290	-	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	-48,364	107,476	-%
May 15, 2024	Royal Bank of Canada	reduced	-99.4	-69,000	-	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	2,760	2,760	-%
May 14, 2024	Qube Research & Technologies Ltd	unchanged	-	-4.00	8.00	-%

Are Funds Buying or Selling MEIP?

Are funds buying MEIP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MEIP

No. of Funds

Unveiling MEI Pharma Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	tang capital partners lp	4.9%	326,084	SC 13G/A
Feb 13, 2024	vanguard group inc	5.85%	389,807	SC 13G/A
Nov 01, 2023	anson funds management lp	9.2%	611,440	SC 13D/A
Oct 24, 2023	anson funds management lp	9.2%	611,440	SC 13D/A
Oct 13, 2023	anson funds management lp	7.4%	490,840	SC 13D/A
Sep 26, 2023	anson funds management lp	6.9%	460,840	SC 13D/A
Sep 22, 2023	anson funds management lp	6.4%	428,800	SC 13D/A
Sep 15, 2023	anson funds management lp	4.9%	326,400	SC 13D/A
Aug 08, 2023	anson funds management lp	4.9%	326,400	SC 13D/A
Jul 17, 2023	anson funds management lp	4.9%	326,400	SC 13D/A

Recent SEC filings of MEI Pharma Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
Feb 28, 2024	424B5	Prospectus Filed
Feb 28, 2024	EFFECT	EFFECT
Feb 26, 2024	CORRESP	CORRESP
Feb 23, 2024	UPLOAD	UPLOAD
Feb 21, 2024	8-K	Current Report
Feb 20, 2024	S-3	S-3
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to MEI Pharma Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

MEI Pharma Inc News

Latest updates

MEI Pharma Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-	-	-	65,297,000	1,457,000	5,894,000	32,735,000	8,730,000	11,414,000	9,694,000	11,832,000	7,757,000	7,454,000	8,109,000	12,595,000	6,638,000	25,504,000	1,244,000	1,008,000	1,157,000	1,129,000	1,249,000
Costs and Expenses	-17.6%	9,829,000	11,930,000	10,016,000	12,537,000	22,285,000	23,809,000	26,949,000	27,610,000	31,252,000	29,457,000	27,862,000	22,928,000	24,504,000	28,368,000	19,420,000	12,869,000	13,687,000	13,117,000	13,780,000	12,878,000	13,865,000
Operating Expenses	-	-	-	-	-	12,238,000	-	-	-	13,059,000	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	-100.0%	-	8,018,000	6,531,000	9,967,000	7,181,000	8,496,000	7,486,000	5,771,000	8,934,000	7,926,000	7,909,000	6,634,000	6,215,000	5,650,000	5,915,000	4,528,000	3,864,000	4,195,000	4,130,000	3,744,000	3,631,000
R&D Expenses	33.4%	5,220,000	3,912,000	3,485,000	2,570,000	15,104,000	15,313,000	19,463,000	21,839,000	22,318,000	21,531,000	19,953,000	16,294,000	17,884,000	22,224,000	12,996,000	7,859,000	8,963,000	8,281,000	8,962,000	8,032,000	9,071,000
EBITDA Margin	-	-	-	-	-	-	-0.86	-1.30	-1.33	-1.37	-1.43	-1.40	-1.45	-0.87	-1.00	-1.33	-1.59	-3.68	-3.68	-2.99	-3.41	-9.23
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	16,000	-	-	-8,000	2,000	-	-	-1,000	2,000	-
EBT Margin	-	-	-	-	-	-	-0.87	-1.31	-1.34	-1.38	-1.44	-1.41	-1.45	-0.87	-1.00	-1.34	-1.59	-3.71	-3.70	-3.01	-3.42	-9.25
Net Income	17.5%	-9,127,000	-11,063,000	56,374,000	-10,029,000	-15,438,000	10,253,000	-16,624,000	-16,063,000	-8,725,000	-12,156,000	-17,510,000	-8,378,000	-25,622,000	-8,026,000	712,000	-18,476,000	-4,329,000	-20,217,000	-2,994,000	3,052,000	-17,354,000
Net Income Margin	43.4%	0.39	0.27	0.39	-0.65	-0.64	-0.50	-1.29	-1.34	-1.27	-1.81	-1.66	-1.19	-	-	-	-	-	-	-	-	-
Free Cashflow	73.5%	-2,928,000	-11,055,000	-18,491,000	-11,302,000	-12,600,000	-14,333,000	-14,845,000	-15,810,000	-13,552,000	-8,617,000	-7,729,000	-11,265,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-9.3%	71.00	79.00	101	121	134	42.00	164	178	194	85.00	176	174	186	204	214	210	97.00	107	69.00	83.00	86.00
Current Assets	-10.3%	59.00	66.00	88.00	108	120	40.00	149	167	183	82.00	167	165	177	194	204	209	95.00	106	68.00	82.00	85.00
Cash Equivalents	-54.2%	2.00	5.00	3.00	17.00	9.00	38.00	15.00	16.00	53.00	81.00	16.00	9.00	10.00	10.00	11.00	12.00	7.00	9.00	6.00	10.00	7.00
Net PPE	-7.5%	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	1.00	1.00	0.00	1.00	0.00	0.00
Liabilities	6.2%	20.00	19.00	20.00	96.00	100	61.00	126	125	127	63.00	142	125	141	125	130	133	22.00	30.00	22.00	35.00	48.00
Current Liabilities	19.6%	10.00	8.00	9.00	20.00	24.00	14.00	23.00	24.00	24.00	13.00	21.00	20.00	33.00	22.00	18.00	14.00	10.00	10.00	10.00	14.00	12.00
Shareholder's Equity	-14.2%	51.00	59.00	81.00	25.00	34.00	48.00	37.00	52.00	68.00	73.00	34.00	49.00	56.00	79.00	84.00	77.00	74.00	77.00	47.00	48.00	38.00
Retained Earnings	-2.5%	-369	-360	-349	-406	-395	-396	-390	-374	-358	-811	-337	-319	-322	-285	-277	-278	-258	-254	-234	-231	-234
Additional Paid-In Capital	0.2%	421	420	431	431	430	837	428	427	426	833	372	369	367	364	362	355	333	332	281	279	272
Shares Outstanding	0%	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	6.00	6.00	6.00	6.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	32.00	-	-	-	353	-	-	-	301	-	-	-	262	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	73.5%	-2,928	-11,055	-18,491	-11,302	-12,600	-14,270	-14,782	-15,504	-13,535	-8,566	-7,721	-11,257	-15,646	4,050	-9,111	69,112	-10,295	-10,481	-14,078	-8,064	-11,342
Share Based Compensation	-21.4%	668	850	363	299	918	813	1,559	650	2,837	2,324	2,539	2,049	2,645	2,609	2,942	1,367	1,550	1,771	2,113	1,448	1,514
Cashflow From Investing	-99.5%	122	24,517	4,957	19,396	-	10,534	13,735	20,112	-14,066	-43,369	14,993	9,988	15,388	-5,144	4,476	-85,048	9,103	-35,316	4,967	9,955	9,768
Cashflow From Financing	100.0%	-	-11,660	-	-	-	-	-40.00	20.00	360	48,865	-194	67.00	126	15.00	3,260	20,829	-8.00	48,451	5,505	273	252

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MEIP Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Revenues	$ 0	$ 5,894	$ 65,297	$ 47,359
Operating expenses:
Research and development	5,220	15,104	12,617	49,880
General and administrative	4,609	7,181	19,158	23,163
Total operating expenses	9,829	22,285	31,775	73,043
(Loss) income from operations	(9,829)	(16,391)	33,522	(25,684)
Other income (expense):
Change in fair value of warrant liability	0	0	0	1,603
Interest and dividend income	706	957	2,669	2,282
Other expense, net	(4)	(4)	(7)	(10)
Total other income, net	702	953	2,662	3,875
Net (loss) income	$ (9,127)	$ (15,438)	$ 36,184	$ (21,809)
Net (loss) income per share - basic and diluted:
Basic	$ (1.37)	$ (2.32)	$ 5.43	$ (3.27)
Diluted	$ (1.37)	$ (2.32)	$ 5.43	$ (3.27)
Weighted-average shares used in computing net (loss) income per share - basic and diluted:
Basic	6,663	6,663	6,663	6,663
Diluted	6,663	6,663	6,663	6,663
Revenue from customers
Revenues	$ 0	$ 5,894	$ 752	$ 47,359
Revenue from collaboration agreements
Revenues	$ 0	$ 0	$ 64,545	$ 0

MEIP Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Jun. 30, 2023
Current assets:
Cash and cash equivalents	$ 2,368	$ 16,906
Short-term investments	54,184	83,787
Unbilled receivables	0	85
Prepaid expenses and other current assets	2,814	6,750
Total current assets	59,366	107,528
Operating lease right-of-use asset	10,836	11,972
Property and equipment, net	1,058	1,309
Total assets	71,260	120,809
Current liabilities:
Accounts payable	3,176	6,134
Accrued liabilities	5,388	12,461
Deferred revenue	0	317
Operating lease liability	1,052	1,428
Total current liabilities	9,616	20,340
Deferred revenue, long-term	0	64,545
Operating lease liability, long-term	10,615	11,300
Total liabilities	20,231	96,185
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock, $0.01 par value; 100 shares authorized; none outstanding	0	0
Common stock, $0.00000002 par value; 226,000 shares authorized; 6,663 shares issued and outstanding at March 31, 2024 and June 30, 2023.	0	0
Additional paid-in capital	420,842	430,621
Accumulated deficit	(369,813)	(405,997)
Total stockholders' equity	51,029	24,624
Total liabilities and stockholders' equity	$ 71,260	$ 120,809

About MEI Pharma Inc

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

CEO	Mr. David M. Urso B.A., Esq., J.D.
WEBSITE	meipharma.com
INDUSTRY	Biotechnology
EMPLOYEES	102

MEI Pharma Inc Frequently Asked Questions

What is the ticker symbol for MEI Pharma Inc? What does MEIP stand for in stocks?

MEIP is the stock ticker symbol of MEI Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MEI Pharma Inc (MEIP)?

As of Fri May 17 2024, market cap of MEI Pharma Inc is 20.99 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MEIP stock?

You can check MEIP's fair value in chart for subscribers.

What is the fair value of MEIP stock?

You can check MEIP's fair value in chart for subscribers. The fair value of MEI Pharma Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MEI Pharma Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MEIP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MEI Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether MEIP is over valued or under valued. Whether MEI Pharma Inc is cheap or expensive depends on the assumptions which impact MEI Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MEIP.

What is MEI Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, MEIP's PE ratio (Price to Earnings) is 0.8 and Price to Sales (PS) ratio is 0.31. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MEIP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on MEI Pharma Inc's stock?

In the past 10 years, MEI Pharma Inc has provided -0.063 (multiply by 100 for percentage) rate of return.